user

Clinical efficacy, safety and inhibition of joint destruction of adalimumab in the treatment of moderate to severe psoriatic arthritis: 48-week results of the ADEPT trial

被引：0
|
作者：
Mease, P
Gladman, D
Ritchlin, C
Weinberg, M
机构：
[1] Swedish Med Ctr, Seattle, WA USA
[2] Univ Toronto, Toronto, ON, Canada
[3] Univ Rochester, Sch Med & Dent, Rochester, NY USA
[4] Abbott Labs, Abbott Pk, IL 60064 USA
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2006年 / 54卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
下载
收藏
页码：AB214 / AB214
页数：1
相关论文
共 50 条
  • [1] Clinical efficacy and safety of adalimumab for psoriatic arthritis: 48-week results of ADEPT
    Mease, PJ
    Gladman, DD
    Ritchlin, CT
    Ruderman, EM
    Choy, EHS
    Steinfeld, SD
    Perdok, R
    Sasso, EH
    Weinberg, MA
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S215 - S215
  • [2] Inhibition of joint destruction in PsA with adalimumab: 48-week results of ADEPT.
    Mease, P
    Sharp, J
    Ory, P
    Gladman, D
    Ritchlin, C
    Choy, E
    Perdok, R
    Weinberg, M
    Sasso, E
    ARTHRITIS AND RHEUMATISM, 2005, 52 (09): : S631 - S631
  • [3] Adalimumab is effective against skin and joint disease in psoriatic arthritis patients: 48-week results of ADEPT
    Mease, P. J.
    Gladman, D. D.
    Ritchlin, C. T.
    Ruderman, E. M.
    Choy, E. H. S.
    Steinfield, S. D.
    Sharp, J. T.
    Ory, P.
    Wang, H.
    Sasso, E.
    RHEUMATOLOGY, 2006, 45 : I68 - I69
  • [4] Long-term efficacy, safety, and inhibition of joint destruction by adalimumab in psoriatic arthritis: Results from ADEPT
    Mease, Philip J.
    Gladman, Dafna
    Ritchlin, Christopher
    Sasso, Eric
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 (07) : 1820 - 1820
  • [5] 24-Week efficacy and safety results from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT)
    Mease, PJ
    Choy, EHS
    Gladman, DD
    Ritchlin, CT
    Ruderman, EM
    Steinfeld, SD
    Weinberg, MA
    RHEUMATOLOGY, 2005, 44 : I3 - I3
  • [6] Adalimumab treatment with and without methotrexate in patients with moderate to severe psoriatic arthritis: Results from adept
    Kavanaugh, AF
    Ritchlin, CT
    Malaise, MG
    Wordsworth, P
    Birbara, CA
    Weinberg, MA
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 325 - 325
  • [7] Adalimumab (Humira®) treatment leads to long-term safety and efficacy in children with juvenile rheumatoid arthritis (JRA):: 48-week results
    Ruperto, N.
    Lovell, D. J.
    Jung, L.
    Reiff, A.
    Nemcova, D.
    Jarosova, K.
    Prieur, A.
    Sandborg, C.
    Rovensky, J.
    Bohnsack, J.
    Minden, K.
    Weiner, L. W.
    Vehe, R.
    Horneff, G.
    Medich, J.
    Carcereri, R.
    McIlraith, M.
    Giannini, E. H.
    Martini, A.
    RHEUMATOLOGY, 2007, 46 : I24 - I24
  • [8] Adalimumab efficacy and safety results in patients with moderate to severe chronic plaque psoriasis with and without psoriatic arthritis
    Menter, MA
    Gordon, K
    Leonardi, C
    Chen, D
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2005, 52 (03) : P174 - P174
  • [9] Long-term efficacy and safety of adalimumab in children with juvenile rheumatoid arthritis (JRA): 48-week results.
    Lovell, D. J.
    Ruperto, N.
    Jung, L.
    Reiff, A.
    Nemcova, D.
    Jarosova, K.
    Prieur, A.
    Sandborg, C.
    Rovensky, J.
    Bohnsack, J.
    Minden, K.
    Weiner, L. Wagner
    Vehe, R.
    Horneff, G.
    Medich, J.
    Giannini, E. H.
    Martini, A.
    ARTHRITIS AND RHEUMATISM, 2006, 54 (09): : S303 - S303
  • [10] Adalimumab is efficacious in treating skin disease in psoriatic arthritis: Subanalysis of moderate versus severe psoriasis in the ADEPT trial
    Gladman, D
    Mease, P
    Kavanaugh, A
    Weinberg, M
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2006, 54 (03) : AB10 - AB11
12345